News

The trial includes an investigational therapy for patients with refractory aggressive non-Hodgkin’s lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified

Both conditions are rare genetic disorders of obesity associated with defects in the MC4 signaling pathway. Phase 2 Trial in Prader-Willi Syndrome (PWS) The first Phase 2 trial

The FDA’s joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee have voted 18 to 6 vote

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. It inhibits a distinct profile of angiogenic tyrosine kinase

The trial named ‘Impact of an optimized Omega 3 formulation on the biochemical and histopathological composition of atheromatous plaques in patients to undergo carotid endarectomy’, will assess the

The AGATA study is designed to evaluate the safety and efficacy of TTP399 following six months administration in subjects with type 2 diabetes mellitus on a stable dose

PKAN is a rare and life-threatening autosomal recessive neurodegenerative disorder. There are no approved treatments currently available for PKAN, which is believed to affect one to three persons

With the acceptance of PIP, the company will be able to submit a marketing authorization application (MAA) in Europe following completion of the Viaskin Peanut phase III program.

As part of the deal, Vertex will have worldwide development and commercial rights to Parion’s investigational ENaC inhibitors, including P-1037 and P-1055. Parion will receive an upfront payment